Real-Life Experience of Continuously Infused Ceftolozane/Tazobactam in Patients with Bronchiectasis and Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infection in the Outpatient Setting

Real-Life Experience of Continuously Infused Ceftolozane/Tazobactam in Patients with Bronchiectasis and Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infection in the Outpatient Setting

(1) Background: Ceftolozane/tazobactam (C/T) is a novel β-lactam/β-lactamase inhibitor with excellent activity against the multidrug-resistant (MDR) <i>P. aeruginosa</i>. Continuous infusion (CI) dosing allows the optimization of pharmacokinetic and pharmacodynamic (PK/PD) properties of...

Full description

Bibliographic Details
Main Authors: Francesco Venuti, Alberto Gaviraghi, Amedeo De Nicolò, Giacomo Stroffolini, Bianca Maria Longo, Alessia Di Vincenzo, Fabio Antonino Ranzani, Matilde Quaranta, Francesca Romano, Eleonora Catellani, Carlotta Marchiaro, Giacoma Cinnirella, Antonio D’Avolio, Stefano Bonora, Andrea Calcagno
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:Antibiotics
Subjects:
ceftolozane/tazobactam
<i>Pseudomonas aeruginosa</i>
bronchiectasis
outpatient parenteral antimicrobial therapy
continuous infusion
therapeutic drug monitoring
Online Access:https://www.mdpi.com/2079-6382/12/7/1214

Internet

https://www.mdpi.com/2079-6382/12/7/1214

Similar Items